CASI Pharmaceuticals Inc ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für CASI Pharmaceuticals Inc zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um CASI Pharmaceuticals Inc zu Deinem Portfolio hinzuzufügen.
- Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 26, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for p...
- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody - Safety profile observed in first four dose cohorts supports continued development - No serious adverse events or dose-limiting toxicities have been reported SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical comp...
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference on ...
- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 2, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a...
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today reported business and financial results for the quarter ended June 30, 2025 (the "second quarter"). "We are focused on adva...
SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 ...
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope Phase 1 study in adults with active and chronic active renal allograft AMR planned to initiate AMR is a leading cause of kidney transplant loss, leading to dialysis and/or repeat renal transplant SAN FRANCISCO, CA / ACCESS Newswire / August 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clin...
-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1B+ raised and multiple company exits by acquisition -- CID-103 is a potential best in class, ...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.